Sie suchten nach: intrakranijalnim (Kroatisch - Englisch)

bolesnici s intrakranijalnim krvarenjem u anamnezi.
patients with a history of intracranial haemorrhage (ich).

osobito su zabrinjavajuća izvješća o intrakranijalnim krvarenjima, koja su često smrtonosna.
reports of intracranial bleeding, many of which are fatal, are of particular concern.

jedan je bolesnik doživio hipertenzivnu encefalopatiju praćenu intrakranijalnim krvarenjem petog dana liječenja, što je rezultiralo prekidom primjene fondaparinuksa.
one experienced hypertensive encephalopathy accompanied by intracranial bleeding on day 5 of therapy resulting in fondaparinux discontinuation.

sufentanil je potrebno koristiti s oprezom u bolesnika koji mogu biti naročito podložni učincima na mozgu uslijed zadržavanja co2 poput bolesnika s dokazanim povećanim intrakranijalnim tlakom ili smanjenom sviješću.
sufentanil should be used with caution in patients who may be particularly susceptible to the cerebral effects of co2 retention, such as those with evidence of increased intracranial pressure or impaired consciousness.

opioidi mogu povisiti tlak cerebrospinalne tekućine što može uzrokovati napadaje, stoga je opioide potrebno koristiti uz oprez u bolesnika s ozljedom glave, intrakranijalnim lezijama i drugim okolnostima u kojima bi cerebrospinalni tlak mogao biti povišen ili u bolesnika s napadajima u anamnezi.
opioids may elevate cerebrospinal fluid pressure, which may cause seizures, so opioids should be used with caution in patients with head injury, intracranial lesions, other circumstances where cerebrospinal pressure may be increased, or history of seizure.

primjena tikagrelora kontraindicirana je kod bolesnika s aktivnim patološkim krvarenjem, kod bolesnika s intrakranijalnim krvarenjem u anamnezi, te kod bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
the use of ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial haemorrhage, and in patients with severe hepatic impairment (see section 4.3).

u kliničkim ispitivanjima asfotaze alfa, nuspojave kraniosinostoze (povezane s povećanim intrakranijalnim tlakom), uključujući pogoršanje postojeće kraniosinostoze, zabilježene su u bolesnika s hipofosfatazijom u dobi od < 5 godina.
in asfotase alfa clinical studies adverse events of craniosynostosis (associated with increased intracranial pressure), including worsening of pre-existing craniosynostosis have been reported in hypophosphatasia patients < 5 years of age.